- Clozapine is the most effective treatment for treatment-resistant schizophrenia and consistently linked with reduced suicidal behaviour.
- Use remains markedly limited despite advances in pharmacovigilance, haematological monitoring and individualised prescribing strategies.
- Psychiatry often emphasises treatment-attributable mortality while underplaying severe mental illness lethality, particularly suicide, with clozapine exposing this conceptual tension.
BJPsych Bull. 2026 Oct 19:1-3. doi: 10.1192/bjb.2026.10317. Online ahead of print.
ABSTRACT
Clozapine remains the most effective treatment for treatment-resistant schizophrenia and one of the few psychiatric medications consistently associated with reduced suicidal behaviour. Nevertheless, its use remains markedly limited despite advances in pharmacovigilance, haematological monitoring and individualised prescribing strategies. This editorial examines whether psychiatry may continue to evaluate clozapine through historically inherited models of risk perception that emphasise treatment-attributable mortality while insufficiently incorporating the lethality of severe mental illness itself, particularly suicide. Clozapine therefore represents not only a psychopharmacological treatment, but also a revealing case study in how psychiatry conceptualises competing forms of mortality.
PMID:42894411 | DOI:10.1192/bjb.2026.10317
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
Save as PDF
⭐ My Revision List

